A 76-WEEK, WORLDWIDE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLEDSTUDY TO ASSESS THE TOLERABILITY AND EFFICACY OF ANACETRAPIB WHEN ADDED TO ONGOINGTHERAPY WITH A STATIN IN PATIENTS WITH CORONARY HEART DISEASE (CHD) OR CHD RISK-EQUIVALENT DISEASE: EVALUATION OF PLASMA ANACETRAPIB CONCENTRATIONS, LIPID LEVELSAND PREGNANCY OUTCOMES (WOMEN OF CHILD-BEARING POTENTIAL) IN PATIENTS WHO WEREPREVIOUSLY TREATED WITH ANACETRAPIB

Not Applicable

• Conditions: -E78 Disorders of lipoprotein metabolism and other lipidaemias; Disorders of lipoprotein metabolism and other lipidaemias; E78

• Registration Number: PER-056-13
• Lead Sponsor: MERCK SHARP & DOHME PERU S.R.L.,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-12-11
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. DEFINE study patients who took at least one dose of anacetrapib and are not currently enrolled in the ongoing PN 019-12 study.
2. Patients who have completed or discontinued from the PN 019-12 study.
3. Patient has an understanding of the study procedures and agrees to participate in the study by giving written informed consent.

Exclusion Criteria

Please refer to the Study Design

Study & Design

• Study Type: Interventional
• Study Design: Not specified